Denali Therapeutics (DNLI) Gains from Investment Securities: 2017-2025
Historic Gains from Investment Securities for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2025 value amounting to $1.4 million.
- Denali Therapeutics' Gains from Investment Securities fell 94.33% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 31.37%. This contributed to the annual value of $32.3 million for FY2024, which is 1077833.33% up from last year.
- Per Denali Therapeutics' latest filing, its Gains from Investment Securities stood at $1.4 million for Q3 2025, which was down 44.08% from $2.4 million recorded in Q2 2025.
- Denali Therapeutics' 5-year Gains from Investment Securities high stood at $24.0 million for Q3 2024, and its period low was -$46,000 during Q3 2022.
- For the 3-year period, Denali Therapeutics' Gains from Investment Securities averaged around $5.8 million, with its median value being $2.4 million (2025).
- Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 150.00% in 2022, then soared by 832,400.00% in 2024.
- Over the past 5 years, Denali Therapeutics' Gains from Investment Securities (Quarterly) stood at $210,000 in 2021, then crashed by 105.71% to -$12,000 in 2022, then soared by 91.67% to -$1,000 in 2023, then skyrocketed by 832,400.00% to $8.3 million in 2024, then crashed by 94.33% to $1.4 million in 2025.
- Its last three reported values are $1.4 million in Q3 2025, $2.4 million for Q2 2025, and $4.4 million during Q1 2025.